NCT05894928View on ClinicalTrials.gov

A Study to Evaluate the Effect of Cholestyramine on LOXO-783 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

21

Participants

Timeline

Start Date

June 7, 2023

Primary Completion Date

July 9, 2023

Study Completion Date

July 9, 2023

Conditions

Healthy

Interventions

DRUG

LOXO-783

Administered orally.

DRUG

Cholestyramine

Administered orally.

Trial Locations (1)

75247

Labcorp Clinical Research Unit, Dallas

Sponsors

Collaborators (1)

Loxo Oncology, Inc.

All Listed Sponsors

collaborator

Loxo Oncology, Inc.

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY